Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study

Philippe J. Caron, John S. Bevan, Stephan Petersenn, Aude Houchard, Caroline Sert, Susan M. Webb

Research output: Contribution to journalArticleResearchpeer-review

15 Citations (Scopus)

Abstract

© 2015, The Author(s). Purpose: To evaluate the effects of lanreotide Autogel on patient-reported outcomes and association with biochemical control, using PRIMARYS data. Methods: PRIMARYS was a 1-year, open-label study of lanreotide Autogel (Depot in USA) 120 mg every 4 weeks in 90 treatment-naïve patients with acromegaly. Symptoms were assessed using Patient-assessed Acromegaly Symptom Questionnaire (PASQ) and health-related quality of life (HRQoL) using the AcroQoL questionnaire. Correlations between PASQ and AcroQoL scores, and between PASQ/AcroQoL and growth hormone (GH)/insulin-like growth factor-1 (IGF-1) levels were also evaluated (post hoc). Results: Acromegaly symptoms and HRQoL significantly improved from week 12 to week 48, with modest correlations at week 48 between PASQ total score (R = –0.55, p < 0.0001) and AcroQoL global and physical scores (R = –0.67, p < 0.0001). Approximately 60 % of patients achieved a minimal important difference (MID; improvement >50 % of baseline standard deviation) in PASQ total score and >40 % achieved a MID in AcroQoL global score (post hoc). Changes in PASQ scores were similar in biochemically controlled (GH levels ≤2.5 μg/L and normal IGF-1 levels) and uncontrolled groups, while changes in global and psychological AcroQoL scores were greater in the controlled group. There was no correlation between changes in PASQ or AcroQoL scores and changes in GH or IGF-1 levels. Conclusions: Primary treatment with lanreotide Autogel over 1 year was associated with rapid and sustained improvements in clinical signs and symptoms and HRQoL in patients with acromegaly. Improvements in HRQoL, but not symptoms, were greater in those achieving biochemical control (ClinicalTrials.gov: NCT00690898; EudraCT: 2007–000155–34).
Original languageEnglish
Pages (from-to)149-157
JournalPituitary
Volume19
Issue number2
DOIs
Publication statusPublished - 1 Apr 2016

Keywords

  • Acromegaly
  • Lanreotide Autogel
  • Quality of life
  • Symptoms

Fingerprint Dive into the research topics of 'Effects of lanreotide Autogel primary therapy on symptoms and quality-of-life in acromegaly: data from the PRIMARYS study'. Together they form a unique fingerprint.

Cite this